TABLE 3.
Tumors | Bacterial signals | Activated TLRs | Effects | References |
Lower gastrointestinal tumor | Helicobacter pylori | TLR2 upregulation | Proliferation of intestinal epithelial cells | Huang et al., 2007 |
Fusobacterium nucleatum | TLR2/TLR4 | Proliferation of cancer cells Resistance to chemotherapy in CRC | Yu et al., 2017; Sun et al., 2019 | |
LPS | TLR4 | M2 macrophages switch and secretion of cytokines in CRC | Li et al., 2019 | |
Esophageal adenocarcinoma | Gram negative bacteria | TLR4 | Inflammation, apoptosis blockage, innate, and adaptive immune responses | Neto et al., 2016 |
Oral squamous cell carcinoma | LPS | TLR4 | Cancer progression and migration Tumor escape | Huang et al., 2005; Kurago et al., 2008; He et al., 2015; Zhang et al., 2019 |
Pancreatic cancer | Distal microbial dysbiosis | TLR2 and TLR5 upregulation | Immunosuppressive phenotype, T cells anergy and increased tumor growth | Pushalkar et al., 2018 |
Liver cancer | LPS | TLR4 | Hepatocellular carcinoma promotion, proliferation and prevention of apoptosis | Dapito et al., 2012 |
Lung cancer | Pneumotype supraglottic predominant taxa (SPT) | TLR2/4 | Attenuated immune responses of alveolar macrophages | Segal et al., 2016 |
Lactobacillus, Streptococcus, and Staphylococcus | TLR-MyD88 dependent pathways | Expansion of IL-17-producing γδ T cells | Jin et al., 2019 | |
Staphylococcus aureus | TLR2 | Recruitment and polarization of CCR2 + CD11B + monocytes into M2 alveolar macrophages | Wang et al., 2013 | |
Breast cancer | Lower number of bacteria | TLR2, 5 and 9 | Lower pro-inflammatory cytokines as IL-12A | Xuan et al., 2014 |
LPS | TLR4 | Metastasis | Beutler, 2000 | |
Pseudomonas aeruginosa | TLR4 | Metastasis | Li et al., 2017 |
The table shows TLRs activated in different tumors (lower and upper gastrointestinal, pancreas, liver, lungs, and breast) by different bacterial signals, derived from microbial changes at the tumor site (dysbiosis). On the right, references are reported.